PharmAbcine Inc.
KRX
₩2,915.00
+0.00%
Delayed · cached 15 min
✓Strengths
- Moderate debt: debt-to-equity of 0.75.
- Current assets comfortably cover current liabilities (current ratio 2.34).
- Sales have compounded about 174% a year over five years.
!Watch-points
- Thin interest cover: operating profit covers interest only about -33.2 times.
- Return on equity is on the lower side at -12.3%.
- Return on capital employed is on the lower side at -23.2%.
- The company reported a net loss in the latest period.
These points are generated automatically from the company’s reported figures to highlight what stands out. They are descriptive observations for educational purposes only — not advice or a recommendation to buy, sell, or hold.
Forensic Checks
Altman Z-ScoreDistress zone
-1.24
In Altman’s study, scores in this range were associated with a higher incidence of financial distress.
Computed without the market-value term.
Piotroski F-ScoreWeak
2 / 4
The F-Score adds one point for each of several year-on-year signs of improving profitability, lower leverage and better efficiency. Higher is generally stronger.
Based on 4 of the 9 signals — the rest need data not available for this stock.
These are well-known academic screening models, shown for educational context only. They describe historical financial patterns and are not predictions, advice, or a recommendation to buy, sell, or hold.
Key Ratios
Current Price₩ 2,915.00
High / Low₩ 2,915.00 / 115.00
Book Value₩ 518.26
ROCE-23.16%
ROE-12.29%
Debt to Equity0.75
Current Ratio2.34
EPS₩ -64.00
PAT Margin-55.45%
ICR-33.17
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity